BackZenas BioPharma Overview
Zenas BioPharma, Inc.

Zenas BioPharma Target Price

Analysts' average 12-month price target for Zenas BioPharma is $27.

Get informed when a big investor buys or sells

+ Follow

Share Price

$30.5

Average Target Price

$27.0011.5% downside

2 analysts in the last 4 months

High: $32 | Low: $22

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-14Morgan Stanley$324.9% upsideOpen
2026-05-14Morgan Stanley$2227.9% downsideOpen
2026-01-06JefferiesRoger Song$4857.4% upsideOpen
2026-01-05Morgan Stanley$1937.7% downsideOpen
2025-10-28H.C. Wainwright$4444.3% upsideOpen
2025-10-27Morgan StanleySean Laaman$3411.5% upsideOpen
2025-10-27JefferiesRoger Song$5270.5% upsideOpen
2024-10-08JefferiesRoger Song$3514.8% upsideOpen

Zenas BioPharma (ZBIO) FAQ

Zenas BioPharma's target price stands at $27. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $27 for ZBIO implies 11.5% downside versus today's price ($30.5). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Zenas BioPharma's target price evolved across reporting periods, while the comparison chart places ZBIO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Zenas BioPharma's reading of $27 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.